Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency.

@article{Atkins2007ResultsOT,
  title={Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency.},
  author={Clarke E Atkins and Bruce W Keene and William A. Brown and Julie R Coats and Mary Ann Crawford and Teresa C DeFrancesco and N Joel Edwards and Phillip R Fox and Linda B. Lehmkuhl and M.W. Luethy and Kathryn M. Meurs and J Petrie and Frank S. Pipers and Steven L. Rosenthal and Jennifer A Sidley and J Straus},
  journal={Journal of the American Veterinary Medical Association},
  year={2007},
  volume={231 7},
  pages={
          1061-9
        }
}
OBJECTIVE To determine the efficacy of long-term enalapril administration in delaying the onset of congestive heart failure (CHF). DESIGN Placebo-controlled, double-blind, multicenter, randomized trial. ANIMALS 124 dogs with compensated mitral valve regurgitation (MR). PROCEDURES Dogs randomly assigned to receive enalapril or placebo were monitored for the primary endpoint of onset of CHF for < or = 58 months. Secondary endpoints included time from study entry to the combined endpoint of… 

Figures and Tables from this paper

Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.

Pimobendan plus conventional therapy prolongs time to sudden death, euthanasia for cardiac reasons, or treatment failure in dogs with CHF caused by MMVD compared with benazeprilplus conventional therapy.

Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases.

BNZ had beneficial effects in asymptomatic dogs other than C KC and KC affected by MVD with moderate-to-severe MR, and no effect of the BNZ treatment was observed in the CKC and KC population.

Efficacy of Pimobendan in the Prevention of Congestive Heart Failure or Sudden Death in Doberman Pinschers with Preclinical Dilated Cardiomyopathy (The PROTECT Study)

Administration of pimobendan to Dobermans with preclinical DCM prolongs the time to the onset of clinical signs and extends survival and treatment of dogs in the preclinical phase of this common cardiovascular disorder can lead to improved outcome.

Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease.

Spironolactone added to conventional cardiac therapy decreases the risk of reaching the primary endpoint (ie, cardiac-related death, euthanasia, or severe worsening) in dogs with moderate to severe MR caused by MMVD.

Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study—A Randomized Clinical Trial

Administration of pimobendan to dogs with MMVD and echocardiographic and radiographic evidence of cardiomegaly results in prolongation of preclinical period and is safe and well tolerated.

Short Term Echocardiographic and Clinical Effects of Ramipril on Dogs with Asymptomatic Degenerative Mitral Valve Disease

Cardiac chamber size, systolic function and severity of mitral regurgitation were not significantly different between the 2 groups throughout the study period, and ramipril did not affect cardiac size, severity of Mitral Regurgitation and systols in 91-day study period.

Term Echocardiographic and Clinical Effects of Ramipril on Dogs with Asymptomatic Degenerative Mitral Valve Disease

Cardiac chamber size, systolic function and severity of mitral regurgitation were not significantly different between the 2 groups throughout the study period, and ramipril did not affect cardiac size, severity of Mitral Regurgitation and systols in 91-day study period.

Long‐term Outcome of Irish Wolfhound Dogs with Preclinical Cardiomyopathy, Atrial Fibrillation, or Both Treated with Pimobendan, Benazepril Hydrochloride, or Methyldigoxin Monotherapy

In IW dogs with preclinical DCM, AF or both, pimobendan monotherapy significantly prolonged time to onset of CHF or sudden death than did monotherapy with benazepril HCl or methyldigoxin.

DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.

Effects of the angiotensin-converting enzyme inhibitor alacepril in dogs with mitral valve disease

Univariate binomial logistic regression analyses showed that high atrial natriuretic peptide level, N-terminal pro-B-type natriurestic peptides level, and E wave velocity at baseline were significantly correlated with alacepril inefficacy.
...

References

SHOWING 1-10 OF 65 REFERENCES

Effects of enalapril maleate on survival of dogs with naturally acquired heart failure. The Long-Term Investigation of Veterinary Enalapril (LIVE) Study Group.

Use of enalapril in combination withstandard treatment (diuretics with or without digoxin) appears to be beneficial over an extended period, compared with standard treatment alone.

Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation.

Long-term treatment with enalapril in asymptomatic dogs with MVD and MR did not delay the onset of heart failure regardless of whether or not cardiomegaly was present at initiation of the study.

Controlled clinical evaluation of enalapril in dogs with heart failure: results of the Cooperative Veterinary Enalapril Study Group. The COVE Study Group.

  • J. Woodfield
  • Medicine
    Journal of veterinary internal medicine
  • 1995
The clinical efficacy and safety of enalapril were evaluated in dogs with moderate or severe heart failure and five dogs had to be removed from the study as a result of azotemia.

Acute and short-term hemodynamic, echocardiographic, and clinical effects of enalapril maleate in dogs with naturally acquired heart failure: results of the Invasive Multicenter PROspective Veterinary Evaluation of Enalapril study. The IMPROVE Study Group.

  • D. Sisson
  • Medicine
    Journal of veterinary internal medicine
  • 1995
This study shows the beneficial hemodynamic and clinical effects of adding enalapril to conventional therapy for dogs with heart failure and significantly greater decreases in class of heart failure, pulmonary edema score, and mobility score relative to baseline.

Effects of long-term administration of enalapril on clinical indicators of renal function in dogs with compensated mitral regurgitation.

Results suggest that administration of enalapril for up to 2 years did not have any demonstrable adverse effects on renal function in dogs with severe, compensated mitral regurgitation.

Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction.

In dogs with reduced LVEF, long-term therapy with enalapril or metoprolol prevents the progression of LV systolic dysfunction and LV chamber dilation and does not prevent progressive LV enlargement.

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

The angiotensin-converting--enzyme inhibitor enalapril significantly reduced the incidence of heart failure and the rate of related hospitalizations, as compared with the rates in the group given placebo, among patients with asymptomatic left ventricular dysfunction.
...